Comparative Effects of Telmisartan versus Valsartan  on HOMA–IR in type 2 Diabetes Mellitus Patients  with Hypertension

Najlaa Saadi Ismael; Fathel Abaas  Al-hamamy

Volume : IV, Issue : I, January - 2014

Comparative Effects of Telmisartan versus Valsartan on HOMA–IR in type 2 Diabetes Mellitus Patients with Hypertension

Najlaa Saadi Ismael, Fathel Abaas Al Hamamy

Abstract :

The aim of this study was to Compare the effects of telmisartan and valsartan on homeostasis model assessment of insulin resistance (HOMA- IR) in type2 diabetes mellitus (T2DM) with hypertension (HT), a randomized control comparative trial (RCT), open label design was adopted. This study was conducted in the Department of Pharmacology, Mosul College of Medicine, University of Mosul and Al-Waffaa diabetic center, Mosul, Iraq from Feuary 1st, 2012 to March 30th, 2013. Eighty-eight patients with oral hypoglycemic agents were randomly assigned to receive two month treatment telmisartan (n = 46) or valsartan (n = 42). with body mass index (BMI) 31.52±4.73, 30.39±3.95 respectivly. Forty one diabetic normotensive patients (n=41) ,and age ,sex ,BMI ,duration of diabetic disease ,duration of diabetic treatment matched to the diabetic hypertensive patients groups were kept as control group. the percentage of patients receiving each of oral hypoglycemic agents did not differ between groups, the oral hypoglycemic agents remained unchanged during the two- month study period. This study showed that diabetic hypertensive patients have a non significant difference in Glucose, serum insulin and (HOMA- IR) before starting therapy, as compared to diabetic normotensive patients group. telmisartan showed significant reduction in body mass index (BMI) (from 31.52±4.73 to 31.23±4.73), P=0.04, waist circumferences (WC) (from 107.07± 7.29 to 106.37± 6.76), P=0.05. valsartan showed insignificant reduction in BMI (from 30.39± 3.94 to 30.19 ±3.83) P=0.06. and in WC (from 106.43±10.34 to 106.17 ±10.47), P=0.17.

The Homeostasis model assessment (HOMA-IR) as a marker of insulin resistance was decreased significantly in telmisartan group (from 6.32 ± 5.18 to 5.09 ± 4.48, p=0.01) as well as decreased in valsartan group but insignificantly (from 6.86± 6.50 to 5.67 ± 4.01, p=0.07).